Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00539773
  4. Details
NCT00539773 Clinical Trial

Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder

Transitional Carcinoma of Urinary Bladder Clinical Trial

Official title:
Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00539773
Other study ID # RAC#2011-073
Secondary ID
Status Completed
Phase N/A
First received October 4, 2007
Last updated December 16, 2015
Start date September 2007
Est. completion date September 2013

Study information
Verified date December 2015
Source King Faisal Specialist Hospital & Research Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Phase II Trial of concurrent administration of intravesical BCG & Interferon in the treatment and prevention of recurrence of superficial transitional carcinoma of the urinary bladder.

Recruitment information / eligibility
Status Completed
Enrollment 10
Est. completion date September 2013
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with superficial transitional carcinoma of the urinary bladder

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• BCG, Interferon
Chemotherapy

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
King Faisal Specialist Hospital & Research Center

Outcome
Type Measure Description Time frame Safety issue
Primary Efficacy overall No